应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02268 药明合联
未开盘 05-03 16:09:00
20.650
-2.400
-10.41%
最高
23.050
最低
20.050
成交量
220.54万
今开
23.050
昨收
23.050
日振幅
13.02%
总市值
247.31亿
流通市值
247.31亿
总股本
11.98亿
成交额
4,584万
换手率
0.18%
流通股本
11.98亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
药明合联05月02日获主力加仓331万元 环比增加442.62%
自选股智能写手 · 05-02
药明合联05月02日获主力加仓331万元 环比增加442.62%
药明合联(02268)上涨5.25%,报23.05元/股
金融界 · 05-02
药明合联(02268)上涨5.25%,报23.05元/股
药明合联(02268)股价上升5.023%,现价港币$23.0
阿斯达克财经 · 05-02
药明合联(02268)股价上升5.023%,现价港币$23.0
【港股通】药明合联(02268)涨逾3% 民生证券指其业绩持续高增 维持“推荐”评级
金吾财讯 · 05-02
【港股通】药明合联(02268)涨逾3% 民生证券指其业绩持续高增 维持“推荐”评级
【券商聚焦】民生证券指药明合联(02268)大幅提升原材料采购协议上限 维持“推荐”评级
金吾财讯 · 04-30
【券商聚焦】民生证券指药明合联(02268)大幅提升原材料采购协议上限 维持“推荐”评级
药明合联(02268)股价上升8.293%,现价港币$22.2
阿斯达克财经 · 04-29
药明合联(02268)股价上升8.293%,现价港币$22.2
南向资金4月25日净买入药明合联106.25万股 连续5日增持
自选股智能写手 · 04-26
南向资金4月25日净买入药明合联106.25万股 连续5日增持
药明合联(02268)上涨5.06%,报19.94元/股
金融界 · 04-25
药明合联(02268)上涨5.06%,报19.94元/股
港股异动 | 医药股午后拉升走强 创新药政策向好态势明显 二季度后板块有望持续转暖
智通财经 · 04-23
港股异动 | 医药股午后拉升走强 创新药政策向好态势明显 二季度后板块有望持续转暖
生物医药板块午后发力 药明合联(02268)涨8.59% 机构指行业今年依然有结构性增量
金吾财讯 · 04-23
生物医药板块午后发力 药明合联(02268)涨8.59% 机构指行业今年依然有结构性增量
药明合联早盘涨近8% 大摩给予“增持”评级
新浪港股 · 04-23
药明合联早盘涨近8% 大摩给予“增持”评级
港股异动 | 药明合联(02268)现涨超6% 公司业绩翻倍增长 全球产能加速释放
智通财经 · 04-23
港股异动 | 药明合联(02268)现涨超6% 公司业绩翻倍增长 全球产能加速释放
港股医药股多数上涨 药明合联涨近9%
南方财经网 · 04-23
港股医药股多数上涨 药明合联涨近9%
智通港股解盘 | 中国内地力挺香港金融中心地位 腾讯(00700)率先发力
智通财经 · 04-22
智通港股解盘 | 中国内地力挺香港金融中心地位 腾讯(00700)率先发力
药明合联(02268)股价显著上升11.406%,现价港币$19.34
阿斯达克财经 · 04-22
药明合联(02268)股价显著上升11.406%,现价港币$19.34
《大行》大摩降药明合联(02268.HK)目标价至39元 评级“增持”
阿斯达克财经 · 04-18
《大行》大摩降药明合联(02268.HK)目标价至39元 评级“增持”
药明合联04月17日遭主力抛售265万元 环比增加301.52%
自选股智能写手 · 04-17
药明合联04月17日遭主力抛售265万元 环比增加301.52%
药明合联午后急涨逾6% 机构指上市后业务取得进一步突破
新浪港股 · 04-17
药明合联午后急涨逾6% 机构指上市后业务取得进一步突破
港股异动 | 药明合联(02268)午后急涨逾5% 公司为ADC CRDMO龙头 上市后业务取得进一步突破
智通财经 · 04-17
港股异动 | 药明合联(02268)午后急涨逾5% 公司为ADC CRDMO龙头 上市后业务取得进一步突破
药明合联(02268)股价下跌5.234%,现价港币$17.38
阿斯达克财经 · 04-16
药明合联(02268)股价下跌5.234%,现价港币$17.38
加载更多
公司概况
公司名称:
药明合联
所属市场:
SEHK
上市日期:
--
主营业务:
WuXi XDC Cayman Inc是一家主要从事提供抗体偶联药物(ADC)及更广泛生物偶联药物的合同研究、开发和生产服务(CRDMO)的控股公司。该公司通过两个分部开展其业务。按有偿服务基准的研究服务分部透过有偿服务合约向客户提供研究服务。按全时当量基准提供的研究服务分部提供一个项目小组,该小组的员工在特定时间内专门负责客户的研究。基于生物药和小分子药物,该公司还提供跨领域的综合服务,涵盖生物偶联药物及连接子及有效载荷的发现、工艺开发及药品生产质量管理规范(GMP)生产。该公司在国内外市场开展其业务。
发行价格:
--
{"stockData":{"symbol":"02268","market":"HK","secType":"STK","nameCN":"药明合联","latestPrice":20.65,"timestamp":1714723740030,"preClose":23.05,"halted":0,"volume":2205411,"delay":0,"floatShares":1197604500,"shares":1197604500,"eps":0.30228347,"marketStatus":"未开盘","marketStatusCode":0,"change":-2.4,"latestTime":"05-03 16:09:00","open":23.05,"high":23.05,"low":20.05,"amount":45839949,"amplitude":0.130152,"askPrice":20.75,"askSize":3500,"bidPrice":20.65,"bidSize":9000,"shortable":3,"etf":0,"ttmEps":0.28356489945155394,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714959000000},"adr":0,"listingDate":1700150400000,"adjPreClose":23.05,"openAndCloseTimeList":[[1714699800000,1714708800000],[1714712400000,1714723200000]],"volumeRatio":1.0396132436065366,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02268","defaultTab":"news","newsList":[{"id":"2432949623","title":"药明合联05月02日获主力加仓331万元 环比增加442.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432949623","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432949623?lang=zh_cn&edition=full","pubTime":"2024-05-02 16:16","pubTimestamp":1714637805,"startTime":"0","endTime":"0","summary":"05月02日, 药明合联股价涨5.25%,报收23.05元,成交金额2180万元,换手率0.08%,振幅7.53%,量比0.41。药明合联今日主力资金净流入331万元,连续3日净流入,上一交易日主力净流入61万元,今日环比增加442.62%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为33.33%,平均涨幅为2.67%。该股近5个交易日上涨21.71%,主力资金累计净流入655万元;近20日主力资金累计净流入1260万元,其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405021617228b6c6046&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405021617228b6c6046&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432413226","title":"药明合联(02268)上涨5.25%,报23.05元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2432413226","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2432413226?lang=zh_cn&edition=full","pubTime":"2024-05-02 15:05","pubTimestamp":1714633508,"startTime":"0","endTime":"0","summary":"5月2日,药明合联(02268)盘中上涨5.25%,截至15:05,报23.05元/股,成交1323.17万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO),具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告,该公司是全球第二大ADC等生物偶联药物CRDMO,市场份额从2020年的1.8%增长至2022年的9.8%,显示出迅速的业务拓展和市场占有率的提升。截至2023年年报,药明合联营业总收入21.24亿元、净利润2.84亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/02150540509898.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2432448476","title":"药明合联(02268)股价上升5.023%,现价港币$23.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2432448476","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2432448476?lang=zh_cn&edition=full","pubTime":"2024-05-02 15:05","pubTimestamp":1714633500,"startTime":"0","endTime":"0","summary":"[上升股]药明合联(02268) 股价在下午03:05比前收市价上升5.023%,现股价为港币$23.0。至目前为止,今日最高价为$23.0,而最低价为$21.55。总成交量为57.977万股,总成交金额为港币$1.307千万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2405024698/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2432431236","title":"【港股通】药明合联(02268)涨逾3% 民生证券指其业绩持续高增 维持“推荐”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2432431236","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2432431236?lang=zh_cn&edition=full","pubTime":"2024-05-02 14:02","pubTimestamp":1714629739,"startTime":"0","endTime":"0","summary":"金吾财讯 | 药明合联 震荡走高,截至发稿,涨3.20%,报22.6港元,成交额946.2万港元。民生证券发研报指,公司公告,将2024年从药明生物的原材料采购服务协议上限提升145%,将2025年上限提升252%。该行表示,药明合联是全球领先的一站式ADCCRDMO龙头,业绩持续高增长,下游客户需求保持强劲,该行预计2024-2026年公司实现营业收入32.00/47.03/67.26亿元,同比增长50.7%/47.0%/43.0%,归母净利润5.62/9.10/13.71亿元,对应PE为43/27/18倍,维持“推荐”评级。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/MDE2Mjg1ODkyMTQzNDI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MDE2Mjg1ODkyMTQzNDI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1936160","is_publish_highlight":false,"gpt_icon":0},{"id":"2431546933","title":"【券商聚焦】民生证券指药明合联(02268)大幅提升原材料采购协议上限 维持“推荐”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2431546933","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2431546933?lang=zh_cn&edition=full","pubTime":"2024-04-30 14:13","pubTimestamp":1714457617,"startTime":"0","endTime":"0","summary":"金吾财讯 | 民生证券发研报指,药明合联 发布公告,将2024年从药明生物的原材料采购服务协议上限从3260万元提高至8000万元,将2025年上限从2130万元提高至7500万元。对药明生物的原材料需求进一步增长,采购服务协议的所有条款及条件均维持不变。该行续指,药明合联是全球领先的一站式ADCCRDMO龙头,业绩持续高增长,下游客户需求保持强劲,该行预计2024-2026年公司实现营业收入32.00/47.03/67.26亿元,同比增长50.7%/47.0%/43.0%,归母净利润5.62/9.10/13.71亿元,对应PE为43/27/18倍,维持“推荐”评级。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/ZmQxNzMzMGZkNTNkZDQwNzE0NzM5MzEwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZmQxNzMzMGZkNTNkZDQwNzE0NzM5MzEwNQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1936084","is_publish_highlight":false,"gpt_icon":0},{"id":"2431008139","title":"药明合联(02268)股价上升8.293%,现价港币$22.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2431008139","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2431008139?lang=zh_cn&edition=full","pubTime":"2024-04-29 14:34","pubTimestamp":1714372440,"startTime":"0","endTime":"0","summary":"[上升股]药明合联(02268) 股价在下午02:34比前收市价上升8.293%,现股价为港币$22.2。至目前为止,今日最高价为$22.2,而最低价为$20.8。总成交量为295.665万股,总成交金额为港币$6.358千万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2404293927/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2430293728","title":"南向资金4月25日净买入药明合联106.25万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2430293728","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430293728?lang=zh_cn&edition=full","pubTime":"2024-04-26 09:31","pubTimestamp":1714095089,"startTime":"0","endTime":"0","summary":"4月25日, 南向资金增持药明合联106.25万股,连续5日增持。截止当日收盘,港股通共持有药明合联3334.95万股,占流通股2.78%。药明合联近5个交易日上涨12.99%,港股通累计增持207.15万股;近20个交易日上涨11.11%,港股通累计增持1395.05万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042609425087b14436&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042609425087b14436&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430428740","title":"药明合联(02268)上涨5.06%,报19.94元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430428740","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430428740?lang=zh_cn&edition=full","pubTime":"2024-04-25 14:15","pubTimestamp":1714025716,"startTime":"0","endTime":"0","summary":"4月25日,药明合联(02268)盘中上涨5.06%,截至14:15,报19.94元/股,成交2125.17万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO),具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告,该公司是全球第二大ADC等生物偶联药物CRDMO,市场份额从2020年的1.8%增长至2022年的9.8%,显示出迅速的业务拓展和市场占有率的提升。截至2023年年报,药明合联营业总收入21.24亿元、净利润2.84亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/25141540402107.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429153834","title":"港股异动 | 医药股午后拉升走强 创新药政策向好态势明显 二季度后板块有望持续转暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2429153834","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429153834?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:55","pubTimestamp":1713851752,"startTime":"0","endTime":"0","summary":"消息面上,近日,北京市医保局印发《北京市支持创新医药高质量发展若干措施》。东海证券近日研报指出,今年以来包括对创新药的明确支持、集采续约条款的持续优化等,行业政策向好态势明显;二季度以后板块整体有望持续转暖向好。中长期来看,持续看好创新药、特色器械等代表新质生产力发展方向的投资机会;中短期来看,重点关注品牌中药、连锁药店、血制品等低估值、高股息,成长稳健的相关板块及个股的投资机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107395.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429027158","title":"生物医药板块午后发力 药明合联(02268)涨8.59% 机构指行业今年依然有结构性增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2429027158","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2429027158?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:53","pubTimestamp":1713851628,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块午后发力走高,药明合联 涨8.59%,荣昌生物涨6.53%,信达生物涨6.48%,康希诺生物涨6.4%,维亚生物涨5.88%,和黄医药涨5.58%,康方生物涨5.41%。华鑫证券表示,2024年1季度行业增长受到同期基数影响较为明显,如零售药店、POCT等,展望2024年全年,1季度高增长方向具有代表性,其增长趋势有望延续,医药行业依然有结构性增量。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/OTA2NWNmYzE4MTQyOTUwMjEyNTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OTA2NWNmYzE4MTQyOTUwMjEyNTI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1935593","is_publish_highlight":false,"gpt_icon":0},{"id":"2429393661","title":"药明合联早盘涨近8% 大摩给予“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2429393661","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2429393661?lang=zh_cn&edition=full","pubTime":"2024-04-23 11:32","pubTimestamp":1713843178,"startTime":"0","endTime":"0","summary":"药明合联早盘上涨7.79%,现报20.20港元,成交额5216万港元。 近日,大摩发表报告指,将药明合联2024财年的每股盈测上调3%。至于2025至2026财年,则分别下调2%及8%,以反映该行对药明合联更新的收入增长假设,以及公司产能启动导致利润率改善放缓的情况。为反映药明合联2024财年及未来数年进取的资本支出计划。大摩将药明合联目标价由40.6港元下调至39港元,给予“增持”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-23/doc-inasuuwe8190273.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-23/doc-inasuuwe8190273.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429501136","title":"港股异动 | 药明合联(02268)现涨超6% 公司业绩翻倍增长 全球产能加速释放","url":"https://stock-news.laohu8.com/highlight/detail?id=2429501136","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429501136?lang=zh_cn&edition=full","pubTime":"2024-04-23 11:11","pubTimestamp":1713841891,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,药明合联现涨超6%,截至发稿,涨6.51%,报19.96港元,成交额4887.45万港元。消息面上,药明合联2023年财报显示,公司取得收益人民币21.24亿元,同比增加114.4%;公司拥有人应占纯利2.84亿元,同比增加82.1%;经调整净利润强劲增长112%至4.12亿元人民币。天风证券指出,公司上市后业务取得进一步突破,叠加全球ADC行业高景气度,截至2023年12月31日公司未完成订单总量为5.79亿美元,同比增长81.9%。此外,全球产能加速释放,持续扩容赋能全球客户。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107352.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429809181","title":"港股医药股多数上涨 药明合联涨近9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429809181","media":"南方财经网","top":-1,"share":"https://www.laohu8.com/m/news/2429809181?lang=zh_cn&edition=full","pubTime":"2024-04-23 09:55","pubTimestamp":1713837306,"startTime":"0","endTime":"0","summary":"南方财经4月23日电,港股医药股多数上涨,截至发稿,药明合联(01228.HK)涨8.86%、康希诺生物(06185.HK)涨5.26%、药明康德(02359.HK)涨2.85%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404233055623762.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429754929","title":"智通港股解盘 | 中国内地力挺香港金融中心地位 腾讯(00700)率先发力","url":"https://stock-news.laohu8.com/highlight/detail?id=2429754929","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429754929?lang=zh_cn&edition=full","pubTime":"2024-04-22 21:25","pubTimestamp":1713792317,"startTime":"0","endTime":"0","summary":"针锋相对的就是:中国人民解放军信息支援部队成立大会19日隆重举行。这个政策就是力挺香港金融市场,多搞一些增量到港股市场,目前已有72家企业完成赴港首次公开发行备案。机构预计上线后为腾讯24年贡献可观业绩增量。花旗也比较罕见发布研报力挺腾讯 :预测一季度毛利将录14.7%的增长,经调整净利润料增长35%至440亿元人民币。公司宣布派发2023年末期股息每股人民币10.82分,2023年累计派息每股17.64分,保持稳定派息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107042.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429437913","title":"药明合联(02268)股价显著上升11.406%,现价港币$19.34","url":"https://stock-news.laohu8.com/highlight/detail?id=2429437913","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2429437913?lang=zh_cn&edition=full","pubTime":"2024-04-22 15:05","pubTimestamp":1713769500,"startTime":"0","endTime":"0","summary":"[上升股]药明合联(02268) 股价在下午03:05比前收市价显著上升11.406%,现股价为港币$19.34。至目前为止,今日最高价为$19.34,而最低价为$17.26。总成交量为144.351万股,总成交金额为港币$2.658千万。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190515141041255_s.png","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190515141041255_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2404224959/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2428865495","title":"《大行》大摩降药明合联(02268.HK)目标价至39元 评级“增持”","url":"https://stock-news.laohu8.com/highlight/detail?id=2428865495","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2428865495?lang=zh_cn&edition=full","pubTime":"2024-04-18 09:55","pubTimestamp":1713405300,"startTime":"0","endTime":"0","summary":"摩根士丹利发表报告指,鉴于药明合联2023财年的收入基础扩大,加上2025及2026财年的委托生产服务项目预测被下调,该行将公司2024及2025财年的收入预测,分别上调7%及1%。至于2026财年的收入预测则下调4%。另外,该行亦预期公司2023至2026财年的收入年均复合成长率为46%。大摩亦将药明合联2024财年的每股盈测上调3%。大摩将药明合联目标价由40.6港元下调至39港元,评级“增持”。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20231117104105862_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20231117104105862_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1343190/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2428393526","title":"药明合联04月17日遭主力抛售265万元 环比增加301.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428393526","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428393526?lang=zh_cn&edition=full","pubTime":"2024-04-17 16:16","pubTimestamp":1713341804,"startTime":"0","endTime":"0","summary":"04月17日, 药明合联股价涨4.42%,报收17.50元,成交金额3005万元,换手率0.15%,振幅5.73%,量比0.97。药明合联今日主力资金净流出265万元,连续5日净流出,上一交易日主力净流出66万元,今日环比增加301.52%。该股近5个交易日下跌11.47%,主力资金累计净流出567万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出292万元,其中净流出天数为9日。该股主力净额占比0.01%,港股市场排名2501/2627。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171617118b2df857&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171617118b2df857&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428361484","title":"药明合联午后急涨逾6% 机构指上市后业务取得进一步突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2428361484","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2428361484?lang=zh_cn&edition=full","pubTime":"2024-04-17 14:54","pubTimestamp":1713336840,"startTime":"0","endTime":"0","summary":" 药明合联午后急涨5.72%,现报17.72港元,成交额2641.21港元。 国信证券指出,药明合联为全球布局的ADC CRDMO龙头,已建立起全面一体化的一站式CRDMO平台,覆盖ADC CRDMO服务的全流程,综合能力全球领先。随着公司全球产能的不断扩张及IND前项目不断向IND后阶段推进,我们认为公司未来3年业务将保持较快增长。 天风证券表示,公司上市后业务取得进一步突破,叠加全球ADC行业高景气度,截至2023年12月31日公司未完成订单总量为5.79亿美元,同比增长81.9%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-17/doc-inascnpy8645759.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-17/doc-inascnpy8645759.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2428365734","title":"港股异动 | 药明合联(02268)午后急涨逾5% 公司为ADC CRDMO龙头 上市后业务取得进一步突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2428365734","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428365734?lang=zh_cn&edition=full","pubTime":"2024-04-17 14:19","pubTimestamp":1713334773,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,药明合联(02268)午后急涨逾5%,截至发稿,涨5.01%,报17.6港元,成交额2016.67万港元。国信证券指出,药明合联为全球布局的ADC CRDMO龙头,已建立起全面一体化的一站式CRDMO平台,覆盖ADC CRDMO服务的全流程,综合能力全球领先。随着公司全球产能的不断扩张及IND前项目不断向IND后阶段推进,我们认为公司未来3年业务将保持较快增长。天风证券则表示,公司上市后业务取得进一步突破,叠加全球ADC行业高景气度,截至2023年12月31日公司未完成订单总量为5.79亿美元,同比增长81.9%。看好公司处于快速成长阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103770.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2427869955","title":"药明合联(02268)股价下跌5.234%,现价港币$17.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2427869955","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2427869955?lang=zh_cn&edition=full","pubTime":"2024-04-16 10:15","pubTimestamp":1713233700,"startTime":"0","endTime":"0","summary":"[下跌股]药明合联(02268) 股价在上午10:15比前收市价下跌5.234%,现股价为港币$17.38。至目前为止,今日最高价为$18.5,而最低价为$17.38。总成交量为50.9万股,总成交金额为港币$907.21万。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180126135510179_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180126135510179_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2404161267/aamm-all-category","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://wuxixdc.com","stockEarnings":[{"period":"1week","weight":0.0073},{"period":"1month","weight":0.1078},{"period":"3month","weight":0.1614},{"period":"6month","weight":0.0024},{"period":"ytd","weight":-0.3547}],"compareEarnings":[{"period":"1week","weight":0.0467},{"period":"1month","weight":0.1047},{"period":"3month","weight":0.1894},{"period":"6month","weight":0.046},{"period":"1year","weight":-0.0738},{"period":"ytd","weight":0.0838}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"WuXi XDC Cayman Inc是一家主要从事提供抗体偶联药物(ADC)及更广泛生物偶联药物的合同研究、开发和生产服务(CRDMO)的控股公司。该公司通过两个分部开展其业务。按有偿服务基准的研究服务分部透过有偿服务合约向客户提供研究服务。按全时当量基准提供的研究服务分部提供一个项目小组,该小组的员工在特定时间内专门负责客户的研究。基于生物药和小分子药物,该公司还提供跨领域的综合服务,涵盖生物偶联药物及连接子及有效载荷的发现、工艺开发及药品生产质量管理规范(GMP)生产。该公司在国内外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.222222,"avgChangeRate":0.010265},{"month":2,"riseRate":0.666667,"avgChangeRate":0.058284},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.010372},{"month":4,"riseRate":0.555556,"avgChangeRate":0.03555},{"month":5,"riseRate":0.333333,"avgChangeRate":0.006014},{"month":6,"riseRate":0.4,"avgChangeRate":-0.032735},{"month":7,"riseRate":0.4,"avgChangeRate":0.011785},{"month":8,"riseRate":0.4,"avgChangeRate":-0.114063},{"month":9,"riseRate":0.333333,"avgChangeRate":0.019767},{"month":10,"riseRate":0.777778,"avgChangeRate":0.151657},{"month":11,"riseRate":0.333333,"avgChangeRate":0.008796},{"month":12,"riseRate":0.111111,"avgChangeRate":-0.068876}],"exchange":"SEHK","name":"药明合联","nameEN":"WUXI XDC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明合联,02268,药明合联股票,药明合联股票老虎,药明合联股票老虎国际,药明合联行情,药明合联股票行情,药明合联股价,药明合联股市,药明合联股票价格,药明合联股票交易,药明合联股票购买,药明合联股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}